Monocentric prospective randomized controlled open phase IV study to explorate the mechanismen of the synergetic effect of the Crateagus -Extract WS 1442 in addition to endurance training related to quality of life of patients with limited physical potential caused by cardiovascular disease (Heart Failure Stade NYHA II).

Trial Profile

Monocentric prospective randomized controlled open phase IV study to explorate the mechanismen of the synergetic effect of the Crateagus -Extract WS 1442 in addition to endurance training related to quality of life of patients with limited physical potential caused by cardiovascular disease (Heart Failure Stade NYHA II).

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Crataegus (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dr. Willmar Schwabe Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2012 Additional trial identifier 2009-111 identified as reported by German Clinical Trials Register.
    • 25 Aug 2011 New source identified and integrated (German Clinical Trials Register DRKS00000259).
    • 25 Aug 2011 Status changed from recruiting to completed as reported by German Clinical Trials Register
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top